Lupus News Today Home | Lupus News Today
网页Parvovirus, mpox, and COVID-19: 3 reasons to heighten precautions. Summer news reports show that COVID-19 is surging again. The World Health Organization has declared the mpox outbreak a global health emergency. And human parvovirus B19, which can cause fifth disease, is spreading across the U.S. Scientists are finding that, in some cases ...
1st patient enrolled in global Phase 2 trial of daxdilimab for...
网页2023年5月18日 · A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative lupus nephritis (LN) — a lupus complication marked by kidney damage — has enrolled its first patient.
Phase 2 Trial Tests Daxdilimab as Potential DLE Therapy - Lupus …
网页2023年1月5日 · The first patient has been enrolled in RECAST DLE, a Phase 2 study evaluating daxdilimab, a potentially first-in-class therapy for moderate-to-severe discoid lupus erythematosus (DLE), a form of lupus that affects the skin. Horizon Therapeutics, the therapy’s developer, expects to enroll about 100 DLE patients, ages 18–75 whose disease is ...
Lupus overview - Lupus News Today
网页2023年2月9日 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
网页by Alice Melão September 29, 2017. New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study.
Lupkynis protects kidneys in lupus nephritis for up to 3 years
网页2023年7月24日 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
FDA Clears Automated Diagnosis Tests for Lupus and ANCA …
网页2018年6月1日 · The U.S. Food and Drug Administration (FDA) has approved new automated diagnostic tests for lupus and ANCA-associated vasculitis, a form of blood vessel inflammation, Grifols, which will market these tests, announced. The two use the HELIOS system, developed by AESKU, which is the first and only automated system capable of processing and ...
2 New Meds Found to Change Lupus Nephritis Treatment: Report
网页2023年1月23日 · Still many patients on high-dose corticosteroids, report finds. The analysis included data from 962 people with the disease in the U.S., as well as insights from 138 rheumatologists — autoimmune disease specialists — and 104 nephrologists, or …
News Archives - Lupus News Today
网页Joint pain very common in lupus, affects patients’ life quality: Study. The vast majority of people with systemic lupus erythematosus (SLE) experience musculoskeletal symptoms, marked by pain, ache, discomfort, and numbness, often in the joints, primarily the hands, wrists, and knees. That’s according to a study from researchers in Egypt ...
FDA Grants Breakthrough Therapy Status to Gazyva for Treating …
网页2019年9月20日 · The therapy is a monoclonal antibody that binds CD20, a protein found on the surface of certain healthy and malignant B-cells, destroying them.However, its mechanism of action also suggests Gazyva may be useful to prevent excessive inflammation associated with several autoimmune diseases, including lupus. The breakthrough designation for treating adult patients with proliferative lupus ...